Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Revolution Medicines Inc (RVMD)

Revolution Medicines Inc (RVMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,411,730
  • Shares Outstanding, K 168,219
  • Annual Sales, $ 11,580 K
  • Annual Income, $ -436,370 K
  • EBIT $ -653 M
  • EBITDA $ -666 M
  • 60-Month Beta 1.40
  • Price/Sales 628.86
  • Price/Cash Flow N/A
  • Price/Book 4.62

Options Overview Details

View History
  • Implied Volatility 47.09% ( -3.02%)
  • Historical Volatility 46.42%
  • IV Percentile 5%
  • IV Rank 3.08%
  • IV High 147.63% on 07/11/24
  • IV Low 43.90% on 12/09/24
  • Put/Call Vol Ratio 1.76
  • Today's Volume 47
  • Volume Avg (30-Day) 1,095
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 38,465
  • Open Int (30-Day) 33,872

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.00
  • Number of Estimates 10
  • High Estimate -0.92
  • Low Estimate -1.15
  • Prior Year -1.14
  • Growth Rate Est. (year over year) +12.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.53 +3.60%
on 12/20/24
59.72 -26.22%
on 11/26/24
-13.01 (-22.80%)
since 11/20/24
3-Month
42.53 +3.60%
on 12/20/24
62.40 -29.39%
on 11/11/24
-1.36 (-2.99%)
since 09/20/24
52-Week
25.91 +70.08%
on 12/21/23
62.40 -29.39%
on 11/11/24
+18.37 (+71.51%)
since 12/20/23

Most Recent Stories

More News
Revolution Medicines Closes $862.5 Million Underwritten Public Offering of Common Stock

Revolution Medicines closed a public offering of 16.6 million shares, raising $862.5 million for RAS-addicted cancer therapies.Quiver AI SummaryRevolution Medicines, Inc. has successfully completed its...

RVMD : 44.06 (+1.78%)
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

RVMD : 44.06 (+1.78%)
Revolution Medicines Prices Public Offering of Common Stock and Pre-Funded Warrants, Aiming for $750 Million in Proceeds

Revolution Medicines announced a public offering of 14.1 million shares priced at $46 each, aiming for $750 million proceeds.Quiver AI SummaryRevolution Medicines, Inc., a clinical-stage oncology company...

RVMD : 44.06 (+1.78%)
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

RVMD : 44.06 (+1.78%)
Revolution Medicines, Inc. Provides Promising Clinical Updates on RMC-6236 for RAS-Addicted Cancers

Revolution Medicines provides updates on RMC-6236 and RMC-6291 in clinical trials for RAS-addicted cancers.Quiver AI SummaryRevolution Medicines, Inc. provided a clinical update on its RAS(ON) inhibitor...

RVMD : 44.06 (+1.78%)
Revolution Medicines Announces Commencement of Public Offering of Common Stock

RVMD : 44.06 (+1.78%)
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

RVMD : 44.06 (+1.78%)
Revolution Medicines to Host Investor Webcast on RAS(ON) Inhibitor Clinical Updates

Revolution Medicines will host an investor webcast on December 2, 2024, to discuss updates on its RAS(ON) inhibitor portfolio.Quiver AI SummaryRevolution Medicines, Inc., a clinical-stage oncology company...

RVMD : 44.06 (+1.78%)
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

RVMD : 44.06 (+1.78%)
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

RVMD : 44.06 (+1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. Revolution Medicines Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 46.37
2nd Resistance Point 45.29
1st Resistance Point 44.68
Last Price 44.06
1st Support Level 42.99
2nd Support Level 41.91
3rd Support Level 41.30

See More

52-Week High 62.40
Fibonacci 61.8% 48.46
Fibonacci 50% 44.15
Last Price 44.06
Fibonacci 38.2% 39.85
52-Week Low 25.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar